The Global High Content Screening Market accounted for US$ 706.6 million in 2020 and is estimated to be US$ 1652.7 million by 2030 and is anticipated to register a CAGR of 8.9%. High-content screening (HCS), otherwise called high-content analysis (HCA) or cellomics, is a technique that is utilized in natural examination and medication disclosure to distinguish substances like little particles, peptides, or RNAi that change the aggregate of a phone in an ideal way. Henceforth high substance screening is a sort of phenotypic screen led in cells including the examination of entire cells or segments of cells with concurrent readout of a few boundaries. HCS is identified with high-throughput screening (HTS), in which a large number of mixtures are tried in equal for their movement in at least one natural measures, yet includes examines of more perplexing cell aggregates as yields. Phenotypic changes might remember increments or diminishes for the creation of cell items like proteins as well as changes in the morphology (visual appearance) of the cell. Subsequently HCA ordinarily includes mechanized microscopy and picture analysis. Unlike high-content examination, high-content screening infers a degree of throughput which is the reason the expression "screening" separates HCS from HCA, which might be high in content however low in throughput.
The report “Global High Content Screening Market, By Product (Instruments (Cell Imaging Analysis Systems, and Flow Cytometers), Consumables (Reagent and Assay Kits, Micro Plates, and Other Consumables), Software, Services, and Accessories), By Application (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling, and Other Applications), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Government Institute, and Contract Research Organization), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030”
Key Highlights:
- In January 2017, PerkinElmer, Inc. launched the Vectra Polaris robotized quantitative pathology imaging framework. This multi-modular tissue imaging framework empowers specialists to acquire a more profound degree of comprehension of illness instruments identified with new malignancy immunotherapy draws near.
- In November 2016, Merck Millipore worked together with Evotec AG (Germany), to give screening administrations to Merck's assortment of hereditary reagents like CRISPR and shRNA libraries. With Evotec's screening skill, Merck had the option to investigate and distinguish new medication targets.
Analyst View:
The traditional technique for toxicity considers includes the screening of enormous libraries looking for potential medication competitors. This strategy is costly, asset and tedious, and has a low achievement rate. Henceforth, HCS answers for testing the possible harmfulness of synthetics and complex substances are being embraced by drug organizations to work on in vitro poisonousness testing by lessening the time and cost. This is powering the development of the great substance screening market and is required to go about as a significant driver for this market during the estimate time frame.
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global High Content Screening Market, By Product (Instruments (Cell Imaging Analysis Systems, and Flow Cytometers), Consumables (Reagent and Assay Kits, Micro Plates, and Other Consumables), Software, Services, and Accessories), By Application (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling, and Other Applications), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Government Institute, and Contract Research Organization), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030”
To know the upcoming trends and insights prevalent in this market, click the link below:
https://www.prophecymarketinsights.com/market_insight/Global-High-Content-Screening-Market-3913
Key Market Insights from the report:
The Global High Content Screening Market accounted for US$ 706.6 million in 2020 and is estimated to be US$ 1652.7 million by 2030 and is anticipated to register a CAGR of 8.9%. The global high content screening market is segmented based on product, application, end-user, and region.
- By Product, the Global High Content Screening Market is segmented into instruments, consumables, software, services, and accessories.
- By Application, the Global High Content Screening Market is segmented into primary and secondary screening, target identification and validation, toxicity studies, compound profiling, and other applications.
- By End-User, the Global High Content Screening Market is segmented into pharmaceutical and biotechnology companies, academic and government institute, and contract research organization.
- By region, the Global High Content Screening Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Competitive Landscape:
The key players operating the global high content screening market are GE Healthcare, Danaher Corporation, Thermo Fisher Scientific, Perkinelmer Inc., Tecan Group , Biotek Instruments Inc., Becton, Dickinson And Company, Bio-Rad Laboratories, Yokogawa Electric Corporation, and Ncardia.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
Description:This report focuses on the global High Content Screening status, future forecast, growth opportunity, key market and key players.
In 2017, the global High Content Screening market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025.
The key players covered in this studyGE HealthcareDanaher CorporationThermo Fisher Scientific Inc.PerkinElmer Inc.BDBiotek InstrumentsBio-Rad LaboratoriesTecan GroupYokogawa Electric CorporationMerck MilliporeRequest a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/2291822 Market segment by Type, the product can be split intoCell Imaging & Analysis SystemFlow CytometryConsumableSoftwareService Market segment by Application, split intoPrimary & Secondary ScreeningToxicity StudiesTarget Identification & Validation Market segment by Regions/Countries, this report coversUnited StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South America The study objectives of this report are:To analyze global High Content Screening status, future forecast, growth opportunity, key market and key players.To present the High Content Screening development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of High Content Screening are as follows:History Year: 2013-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2025 For the data information by region, company, type and application, 2017 is considered as the base year.
Whenever data information was unavailable for the base year, the prior year has been considered.Browse the complete report @ http://www.orbisresearch.com/reports/index/global-high-content-screening-market-size-status-and-forecast-2018-2025 Some Points from TOC:Chapter One: Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.4.1 Global High Content Screening Market Size Growth Rate by Type (2013-2025)1.4.2 Cell Imaging & Analysis System1.4.3 Flow Cytometry1.4.4 Consumable1.4.5 Software1.4.6 Service1.5 Market by Application1.5.1 Global High Content Screening Market Share by Application (2013-2025)1.5.2 Primary & Secondary Screening1.5.3 Toxicity Studies1.5.4 Target Identification & Validation1.6 Study Objectives1.7 Years Considered Chapter Two: Global Growth Trends2.1 High Content Screening Market Size2.2 High Content Screening Growth Trends by Regions2.2.1 High Content Screening Market Size by Regions (2013-2025)2.2.2 High Content Screening Market Share by Regions (2013-2018)2.3 Industry Trends2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market OpportunitiesIf you have any enquiry before buying a copy of this report@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2291822 ….Continued About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements.
We have vast database of reports from the leading publishers and authors across the globe.
Future Market Insights (FMI), with a sharp focus on emerging regions, delivers key insights on the global High Content Screening Market in its latest report titled, “ High Content Screening (HCS) Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025”.
According to the report, the global High Content Screening (HCS) market is projected to expand at a single-digit CAGR during the forecast period, accounting for US$ 382.9 Mn by 2025.
The global cell analysis instrumentation market is expected to account for US$ 2,120.5 Mn by 2025, registering a CAGR of 6.1% during the forecast period, i.e.
2015–2025.Key players in the High Content Screening (HCS) Market include Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., GE Healthcare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher Corporation (Molecular Devices), Yokogawa Electric Corporation, Sysmex Corporation and Thorlabs Inc.Demand for highly efficient screening systems, owing to increasing drug discovery initiatives among pharmaceuticals and biotechnology companies is anticipated to provide an impetus to the High Content Screening (HCS) market.
“Increasing focus of companies on penetrating untapped markets in countries in Asia Pacific and Latin America, where growth of the biotechnology and biopharmaceuticals industry in increasing, is expected to fuel demand for High Content Screening (HCS) instruments installation in the next five to six years or between 2018 and 2025,”High Content Screening (HCS) instruments are extensively used across end-use industries such as pharmaceuticals and healthcare, biotechnology companies, educational institutions, government organisations, independent contract research organisations and others.
Demand for efficient purification protocols for therapeutic cells is expected to fuel demand for high-end screening system over the next five to six years.Key SegmentBy ProductCell Imaging and Analysis EquipmentHigh Content Screening (HCS) InstrumentsHigh-End High Content Screening (HCS)Mid-End High Content Screening(HCS)Low-End High Content Screening (HCS) InstrumentsFlow CytometersConsumablesSoftwareServices By End-Use Pharmaceutical and HealthcareBiotechnology CompaniesEducational InstitutionsGovernment OrganisationsOthersBy RegionNorth AmericaLatin AmericaWestern EuropeEastern Europe Asia Pacific Excluding Japan (APEJ) Japan Middle East And AfricaFor more insights on the High Content Screening Market, you can request a sample report with TOC at http://www.futuremarketinsights.com/reports/sample/rep-gb-426Geographically, the report focusses on North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific Excluding Japan (APEJ), Japan and Middle East and Africa (MEA).
HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies.Major Growth Drivers:The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.
On the other hand, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.Expected Revenue Growth:MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period.Accessories to Fuel the Growth of high content screening market : HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies.HCS instruments such as flow cytometers and multimode readers have relatively complex technologies.
Experts with a good knowledge of cell-based assays and handling software & instruments are required for their optimum utilization.
A survey conducted by the Association of the British Pharmaceutical Industry (ABPI) in the U.K. revealed a lack of skilled personnel in pharmaceutical companies.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391By product, the HCS instruments segment is expected to dominate the marketThe HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments.
HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companiesExpected Revenue Growth:MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period.Major Growth Drivers:The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.
On the other hand, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.Accessories to Fuel the Growth of high content screening market :HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies.HCS instruments such as flow cytometers and multimode readers have relatively complex technologies.
Experts with a good knowledge of cell-based assays and handling software & instruments are required for their optimum utilization.
A survey conducted by the Association of the British Pharmaceutical Industry (ABPI) in the U.K. revealed a lack of skilled personnel in pharmaceutical companies.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391By product, the HCS instruments segment is expected to dominate the marketThe HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments.
